A new Nature Medicine study identified a 19-protein blood biomarker panel that may help predict when ALS symptoms will emerge in people at elevated genetic risk. The research could eventually improve preventive treatment trials, but the test is not yet ready for routine screening.

Editorial Note

This article is provided for general educational and informational purposes and does not provide medical advice, diagnosis, genetic counseling, or treatment recommendations. ALS is a serious neurological disease, and decisions involving genetic testing, neurological symptoms, predictive testing, or treatment should be discussed with qualified healthcare professionals.

The research discussed here is promising but experimental. The newly identified biomarker panel is not currently a routine screening test for ALS, and the findings should not be interpreted as allowing doctors to predict with certainty whether or exactly when an individual person will develop the disease. Much of the study involved people already known to carry ALS-associated genetic variants.

ALS Research Is Beginning to Look Before Symptoms Appear

For most people, the idea of diagnosing a disease begins when something feels wrong.

A person develops weakness, difficulty speaking, unusual muscle movements, or another symptom. Doctors investigate what is happening, rule out other explanations, and eventually arrive at a diagnosis.

ALS creates a particularly difficult version of that problem because biological changes may already be underway before obvious symptoms appear.

Researchers are now asking a different question: what if doctors could detect that transition before the disease becomes clinically visible?

A new study published July 27 in Nature Medicine provides one of the strongest indications yet that changes in proteins circulating in the blood may help scientists estimate when clinically manifest ALS is approaching in people already at elevated genetic risk. Researchers identified a panel of 19 proteins whose combined pattern predicted progression over time horizons ranging from roughly six months to five years.

The model estimated the timing of disease onset with a mean absolute error of approximately 1.6 years. That level of precision is nowhere near a perfect prediction, but it could be useful for a research field attempting to determine when preventive treatment should begin.

The significance is therefore not that scientists have developed a crystal ball for ALS. It is that they may be getting better at recognizing when the disease is biologically moving from risk toward clinical manifestation.

What Is ALS?

Amyotrophic lateral sclerosis, commonly known as ALS, is a progressive neurodegenerative disease that damages motor neurons, the nerve cells involved in controlling voluntary muscle movement.

As those neurons deteriorate, people can progressively lose strength and eventually experience difficulty walking, speaking, swallowing, and breathing. ALS remains a devastating disease, and researchers have spent decades trying to understand not only how to slow its progression but how early the biological process begins.

That second question is becoming increasingly important.

If significant neurological damage occurs before recognizable symptoms, waiting until the disease becomes obvious may mean losing a valuable opportunity for intervention.

Researchers therefore want biomarkers that can reveal what is happening during the presymptomatic period—the period in which disease-related biology may be changing even though the person does not yet meet the clinical definition of ALS.

Researchers Followed People at Elevated Genetic Risk

The new study was built on a remarkable research project called Pre-symptomatic Familial ALS, or Pre-fALS.

For nearly two decades, researchers led by Michael Benatar and Joanne Wuu at the University of Miami have followed people carrying genetic variants associated with increased ALS risk. Participants have provided clinical information and biological samples over time, allowing scientists to observe what happens before some individuals eventually develop symptoms.

That longitudinal design is extremely important.

Many biomarker studies compare people who already have a disease with healthy controls. Those studies can identify differences, but they cannot necessarily tell researchers which changes happened first.

Pre-fALS provides something much rarer: biological samples from the same people before and around the period when disease becomes clinically apparent.

In the new analysis, researchers examined 516 serial plasma samples from 137 participants. The study included 33 people who underwent phenoconversion, along with people with clinically manifest ALS, presymptomatic genetic-variant carriers, and controls.

That allowed the researchers to search for protein patterns that changed as disease onset approached.

More Than 5,000 Proteins Were Examined

The researchers used a high-throughput proteomic platform to analyze thousands of proteins circulating in blood plasma.

Proteomics can be thought of as a large-scale effort to examine the proteins produced or released by biological systems. Instead of measuring one familiar biomarker, researchers can look across thousands of molecules and search for patterns connected to disease.

NIH reports that the researchers measured more than 5,000 proteins and identified 92 whose levels changed before participants developed clinical manifestations. They then used machine-learning methods to test different combinations and identify the most informative group.

The result was a 19-protein panel.

That multi-protein approach matters because complex diseases rarely produce one perfectly specific biological signal. A combination of markers may capture several processes occurring simultaneously as disease progresses.

The final panel included neurofilament light chain, or NfL, along with other proteins such as NEFL, EDA2R, and CA3 that showed meaningful presymptomatic changes. The paper reported that the combined panel performed better than neurofilament alone when estimating time to phenoconversion.

Neurofilament Was Already an Important Clue

The idea that blood might reveal ALS before symptoms did not begin with this study.

Researchers in the Pre-fALS project previously observed that neurofilament light chain can rise before clinical symptoms emerge.

Neurofilaments are structural components of neurons. When nerve cells become damaged, increased amounts can enter cerebrospinal fluid and eventually the bloodstream.

That makes NfL useful as a sign of neuroaxonal injury.

The limitation is specificity. Elevated neurofilament is not unique to ALS and can occur in other neurological conditions, meaning it does not function as a simple disease-specific yes-or-no marker.

The new research attempts to improve on that limitation by examining a larger biological pattern rather than relying entirely on one protein.

Instead of asking whether NfL is elevated, the researchers are effectively asking whether a particular constellation of protein changes resembles the biological transition toward clinically manifest ALS.

That is a more sophisticated question.

The 19-Protein Panel Predicted Risk Across Several Years

Researchers evaluated how well the panel predicted phenoconversion over time periods ranging from six months to five years.

Across those prediction windows, the models produced cross-validated area-under-the-curve values between 0.80 and 0.89. In diagnostic and predictive research, an AUC of 0.5 represents performance no better than chance, while values approaching 1.0 indicate increasingly strong discrimination.

Those results are encouraging, but they should not be translated into the claim that the blood test is “80% to 89% accurate.”

AUC measures how well a model distinguishes risk groups across possible decision thresholds. It is not the same as telling an individual person that there is an 89% probability they will develop symptoms on a particular date.

The more practically understandable result came from the model's estimate of time to onset.

Researchers reported a mean absolute error of approximately 1.6 years when estimating when phenoconversion would occur.

For everyday medical decision-making, that would still be a large window.

For designing a preventive ALS clinical trial, however, knowing that someone may be approaching the biological transition within the next several years could be dramatically more useful than having no reliable timing estimate at all.

Why Timing Matters So Much for ALS

Predicting risk is only useful if the information can change what happens next.

That is why the ALS findings are particularly interesting now.

Scientists are increasingly developing treatments aimed at specific genetic forms of ALS. One example is tofersen, marketed in the United States as Qalsody, which targets ALS associated with mutations in the SOD1 gene.

The FDA approved tofersen in 2023 through the accelerated-approval pathway for adults with SOD1-associated ALS, based on its effect on plasma neurofilament light chain.

Researchers are also studying whether treatment could begin before symptoms appear.

The ongoing Phase 3 ATLAS trial is evaluating tofersen in presymptomatic adults who carry qualifying SOD1 mutations and have elevated neurofilament levels. ClinicalTrials.gov currently lists the study as active but not recruiting.

That is where a better biomarker panel could become particularly valuable.

Researchers conducting prevention trials need to identify people who are not merely genetically at risk but may be biologically approaching disease onset.

Otherwise, a trial could treat many participants years or decades before they would have become symptomatic, making it difficult to determine whether the therapy actually delayed disease.

Better timing could make preventive trials smaller, more informative, and potentially faster.

This Is Different From Diagnosing Someone Who Already Has ALS

The distinction between diagnostic biomarkers and predictive biomarkers is important.

A diagnostic test asks whether someone currently has a disease.

A predictive or risk biomarker may instead provide information about what could happen in the future.

The new study primarily addresses the second problem.

Researchers were trying to identify biological patterns associated with approaching phenoconversion among people with elevated risk, not create a universal test for everyone experiencing muscle weakness.

That means someone should not read this study and conclude that a routine blood panel can now confirm or rule out ALS.

It cannot.

ALS diagnosis remains a clinical process involving neurological evaluation and other testing.

The new protein panel is best understood as an experimental research tool that may eventually help identify when disease is approaching in carefully selected populations.

The Study Was Partially Replicated in the UK Biobank

One of the more encouraging parts of the research was the investigators' attempt to test whether the findings extended beyond the original Pre-fALS population.

The researchers analyzed information from the UK Biobank, a large biomedical research database containing health and biological information from a much broader population.

They were able to partially replicate several important findings. Presymptomatic increases in proteins including NEFL, EDA2R, and CA3 were observed, and the multi-protein approach again appeared to provide more information about timing than neurofilament alone.

Partial replication strengthens confidence that the findings are not merely an artifact of one highly specialized cohort.

It does not complete the validation process.

The UK Biobank differs from Pre-fALS in important ways, and the authors themselves describe the replication as partial. Larger prospective studies involving more diverse populations will still be necessary before a clinical laboratory could responsibly use this panel to predict ALS onset.

Familial ALS Is Only Part of the Disease

Another limitation concerns genetics.

The Pre-fALS study is uniquely valuable because researchers can identify healthy people who already carry ALS-associated pathogenic variants and follow them over time.

But most ALS cases are not discovered because an unaffected person already knows they carry a high-risk mutation.

That means the immediate clinical application of the biomarker panel is likely to be narrow.

It may be most useful first for people with known familial or genetic risk and for researchers conducting prevention studies.

The broader scientific question is whether similar protein patterns can eventually help identify presymptomatic disease among people without a known ALS-associated mutation.

The UK Biobank findings offer some reason to investigate that possibility, but they do not yet establish a population-wide screening strategy.

A Blood Test Could Change the Definition of “Early” ALS

For decades, “early ALS” generally meant early in the period after symptoms began.

Biomarker research is beginning to challenge that definition.

If researchers can reliably identify biological changes months or years before weakness becomes clinically obvious, the disease may eventually be understood as having a measurable presymptomatic stage.

That transformation has already occurred in other areas of medicine.

Researchers increasingly study Alzheimer's disease through biomarkers that can change well before dementia develops. Cancer researchers use molecular signals to identify some diseases before symptoms appear. Cardiovascular medicine uses cholesterol, blood pressure, and other measurements to estimate future risk rather than waiting for a heart attack.

ALS research may be moving toward a similar model.

The disease would not begin, conceptually, on the day symptoms become noticeable.

That would simply be the point at which the underlying process becomes clinically visible.

Earlier Detection Is Only Valuable If Earlier Treatment Helps

There is an important caution behind all predictive medicine.

Finding disease earlier is not automatically beneficial.

Early detection has the greatest value when it leads to an intervention that meaningfully changes the outcome.

For ALS, that remains an active research question.

Tofersen provides a particularly interesting test case because researchers are actively studying whether treating genetically at-risk people before symptoms emerge can delay clinical disease.

If preventive therapy ultimately proves effective, biomarker timing becomes enormously valuable.

Doctors would need to know not merely who carries a mutation, but when the disease process has advanced enough that intervention should begin.

If effective preventive therapies do not materialize, predictive testing creates a much more difficult ethical situation.

Knowing that symptoms may appear within several years is psychologically and medically very different from knowing that an effective treatment can prevent them.

The science of prediction therefore has to develop alongside the science of prevention.

Predictive Testing Creates Difficult Ethical Questions

Imagine being healthy but carrying an ALS-associated genetic variant.

A physician tells you that a blood test suggests you may be approaching symptom onset.

The estimate could still be wrong by more than a year.

Would you want to know?

Some people would. The information might influence career decisions, financial planning, family discussions, clinical-trial participation, or medical monitoring.

Other people might prefer not to live with an uncertain countdown.

Neither response is unreasonable.

Predictive neurological testing therefore creates questions extending well beyond laboratory science. Genetic counseling, informed consent, psychological support, privacy protections, and careful communication will become increasingly important if tests like this move toward clinical practice.

Medicine has to consider not only whether information can be generated but how that information affects the person receiving it.

False Precision Could Become a Serious Problem

A model producing a 1.6-year average error can be scientifically useful while still being easily misunderstood by the public.

Suppose a future test estimated that someone was two years from symptom onset.

That would not mean symptoms would begin exactly two years later.

Prediction models describe probabilities and expected patterns across populations. Individual outcomes can fall outside those estimates.

Communicating that uncertainty will be essential.

The danger is creating the impression that a biomarker panel functions like a clock counting down toward ALS.

It does not.

The current study shows that biological signals contain meaningful information about proximity to disease onset. It does not establish deterministic timing for each individual.

Medical journalism should preserve that distinction because overstating predictive precision could create unnecessary fear.

This Is Not a Test People Should Request From Their Doctor Yet

The research is exciting enough that some readers may wonder whether they should have their protein levels tested.

For most people, the answer is no.

The 19-protein panel remains a research finding rather than a standard clinical screening test. The model was developed using specialized proteomic measurements and carefully characterized research cohorts.

There is currently no recommendation for population-wide ALS blood screening based on this panel.

Someone experiencing neurological symptoms should seek medical evaluation rather than attempting to interpret individual blood proteins.

Similarly, people with a strong family history of ALS who are concerned about inherited risk may benefit from discussing genetic counseling and appropriate clinical evaluation rather than using consumer testing or attempting to apply research findings on their own.

Research results and clinical tests are not interchangeable.

The Bigger Scientific Shift Is Toward Prevention

The most important aspect of the study may not ultimately be the exact 19 proteins.

It is what scientists are trying to accomplish with them.

Historically, much ALS research has understandably focused on slowing disease after symptoms appear.

Presymptomatic biomarker research points toward a more ambitious goal: preventing or delaying clinically manifest ALS before substantial neurological disability develops.

That requires several scientific advances to come together.

Researchers need to identify people at meaningful risk, determine when the disease process is becoming active, develop treatments capable of modifying that process, and prove that intervening early actually changes the course of disease.

The new protein panel addresses one part of that chain.

It improves scientists' ability to estimate when the disease may be approaching.

The treatment side of the equation still has to catch up.

Why This Research Matters Even If the Test Never Reaches Routine Clinics

Biomarkers can have enormous value without becoming household screening tests.

Clinical trials are one example.

If researchers can identify participants most likely to develop symptoms within several years, they can test preventive treatments much more efficiently.

Biomarkers can also help scientists understand the underlying biology of ALS.

The 92 proteins that changed before phenoconversion may provide clues about processes involving neurons, muscle, inflammation, metabolism, and other biological systems as disease approaches.

Those clues can generate new hypotheses and possibly new therapeutic targets.

The study therefore matters on two levels.

It could eventually contribute to predictive medicine.

It also gives researchers a new view of what ALS looks like biologically before most people would recognize it as ALS at all.

Key Takeaways

A Nature Medicine study published July 27, 2026 identified 92 blood proteins whose levels changed before clinical manifestation of ALS in a longitudinal research cohort. Researchers narrowed those signals to a panel of 19 proteins that provided the strongest combined predictive information.

The model predicted phenoconversion across time horizons ranging from approximately six months to five years and estimated timing with a mean absolute error of about 1.6 years. The researchers also partially replicated key findings using UK Biobank data.

The study does not establish a routine ALS screening test for the general public. Much of the research involved people already known to carry ALS-associated genetic variants, and additional validation is needed.

The research could be especially valuable for preventive clinical trials. An ongoing Phase 3 trial is already evaluating tofersen in certain presymptomatic adults carrying SOD1 mutations, illustrating why researchers need better tools for identifying when disease onset may be approaching.

The larger goal is not simply diagnosing ALS earlier. It is eventually identifying biological disease early enough that treatment might delay or prevent the symptoms and disability that follow.

Frequently Asked Questions

Is there now a blood test that can tell me when I will develop ALS?

No. Researchers have developed an experimental 19-protein predictive model, but it is not a routine clinical test and cannot predict an individual's disease onset with certainty.

How accurate was the prediction?

The study reported a mean absolute error of approximately 1.6 years when estimating time to phenoconversion. Across prediction horizons ranging from six months to five years, cross-validated AUC values ranged from 0.80 to 0.89.

What is neurofilament light chain?

Neurofilament light chain, commonly called NfL, is a structural neuronal protein that can increase in blood when nerve cells are damaged. It has become an important neurological biomarker but is not specific to ALS alone.

Does this research mean ALS can now be prevented?

No. The study improves prediction, not prevention itself. Researchers are investigating whether treatments such as tofersen can benefit certain genetically at-risk people when started before clinical symptoms, but that question is still being studied.

Who might benefit from this research first?

If the findings are validated, the earliest applications may involve people already known to carry ALS-associated genetic variants and researchers conducting preventive clinical trials rather than population-wide screening.

Final Thoughts

ALS has traditionally been a disease medicine confronts after something has already changed.

Weakness appears. Movement becomes difficult. Speech changes. A person seeks answers, and the diagnostic process begins.

This research asks whether that timeline can eventually move backward.

The blood appears to contain biological clues before clinically manifest disease emerges. By following those clues across time, researchers are beginning to estimate when some people at elevated genetic risk may be approaching that transition.

That is a meaningful scientific advance.

It is not yet a clinical solution.

A prediction with an uncertainty measured in years is very different from knowing exactly when disease will begin, and a biomarker is only as valuable as the medical action that follows it.

Still, the direction of the research is important.

The future of ALS medicine may not be limited to treating symptoms earlier after they appear. It may involve recognizing the biological disease before those symptoms begin and intervening during a period when more motor neurons remain intact.

That possibility changes the question researchers are asking.

Instead of only asking, “How can we slow ALS?”

They can increasingly ask, “How early would we have to intervene to keep ALS from becoming clinically manifest in the first place?”

The new 19-protein blood signature does not answer that question by itself.

But it may help researchers identify the window in which an answer could someday matter most.

Support New To Education

New To Education publishes educational health and medical-research coverage designed to help readers understand emerging findings without turning preliminary science into medical advice.

Our goal is to explain what researchers discovered, what the evidence does and does not establish, and why a finding may matter for the future of healthcare.

New Health Research Published July 27, 2026: ALS Prediction, Cancer Genetics, Meal Timing, Saunas, and Sparkling Water

New Blood Test May Predict Alzheimer’s Symptoms Years Before They Begin